Stockscreener 앱 받기
18.59
0.60%
0.11
시간 외 거래:
18.59
전일 마감가:
$18.48
열려 있는:
$18.4
하루 거래량:
343.31K
Relative Volume:
0.44
시가총액:
$905.00M
수익:
$109.79M
순이익/손실:
$-153.49M
주가수익비율:
-5.7916
EPS:
-3.2098
순현금흐름:
$-172.59M
1주 성능:
-1.06%
1개월 성능:
-14.72%
6개월 성능:
+3.57%
1년 성능:
+59.43%
1일 변동 폭
$18.21
$18.89
1주일 범위
$17.94
$19.25
52주 변동 폭
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
18.59 | 899.65M | 109.79M | -153.49M | -172.59M | -3.2098 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
UroGen Pharma Ltd. (URGN) Stock Price Prediction for 2026, 2030-2040 - Traders Union
UroGen Pharma Hits Day High with Strong 7.12% Intraday Surge - Markets Mojo
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Clinical Setbacks and Cash Burn Con - AD HOC NEWS
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Biotech Sector Volatility - AD HOC NEWS
UroGen Pharma (URGN) Highlights Key Findings in Bladder Cancer R - GuruFocus
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence - The Manila Times
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support - GlobeNewswire Inc.
Jobs Data: Is UroGen Pharma Ltd stock showing strong momentumMarket Volume Report & Consistent Profit Trading Strategies - baoquankhu1.vn
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
URGN (UroGen Pharma) NonCurrent Deferred Revenue : $0.0 Mil (As of Dec. 2025) - GuruFocus
How (URGN) Movements Inform Risk Allocation Models - Stock Traders Daily
URGN Technical Analysis & ETF Price Forecast - Intellectia AI
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
UroGen closes up 43% ahead of FDA decision on bladder cancer candidate - MSN
UroGen Pharma Q3 2025 Earnings Preview - MSN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
UroGen Pharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
UroGen grants 51,200 stock units to new hires backing cancer drugs - Stock Titan
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN - MarketBeat
Assessing UroGen Pharma (URGN) Valuation After Recent Share Price Volatility - simplywall.st
Q1 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - MarketBeat
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push - Yahoo Finance
UroGen’s ZUSDURI Data And Reimbursement Progress Shift Risk Reward Profile - simplywall.st
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation - Investing.com Australia
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating - TipRanks
NMIBC Market: Strong Pharma Growth Forecast Through 2034 - openPR.com
Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales - Investing.com Australia
UroGen Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript - Insider Monkey
UroGen refinances debt with $250M facility at 8.25% rate - Investing.com India
UroGen reports $15.8M in ZUSDURI sales, refinances debt By Investing.com - Investing.com Canada
UroGen Pharma Strengthens Balance Sheet, Reports FY25 Results And ZUSDURI Launch Progress - Nasdaq
UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives - simplywall.st
Urogen Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026 - Meyka
UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Stron - GuruFocus
Akin, an Elite Global Law Firm - Akin
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales By Investing.com - Investing.com South Africa
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales - Investing.com Australia
Urogen Pharma (NASDAQ:URGN) Shares Down 13.5%Should You Sell? - MarketBeat
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts - Investing.com Nigeria
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Urogen Pharma Q4 Earnings Call Highlights - MarketBeat
UroGen (URGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
URGN: Analyst Maintains Buy Rating with $33 Target | URGN Stock News - GuruFocus
Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
UroGen Pharma Amends Loan Agreement With Pharmakon Advisors - marketscreener.com
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):